HemoSonics Wins 2025 Medical Device Network Excellence Award in the Marketing Category

Award recognizes HemoSonics’ impactful marketing and ability to communicate the value of its Quantra Hemostasis System, which provides comprehensive blood analysis detailing hemostasis in the operating room in less than 15 minutes

DURHAM, N.C.--(BUSINESS WIRE)--HemoSonics, LLC, a medical device company focused on acute bleeding management, today announced it has won the 2025 Medical Device Network Excellence Award in the Marketing category for its impactful engagement in promoting its Quantra Hemostasis System. The award recognizes HemoSonics’ ability to communicate the value of its Quantra Hemostasis System, engage the healthcare community through educational initiatives, and demonstrate thought leadership in blood management.

HemoSonics’ Quantra Hemostasis System comprises the Quantra Hemostasis Analyzer with QPlus and QStat Cartridges, providing clinicians with information to inform patient-centered decisions on bleeding management in under 15 minutes, thereby improving care and optimizing blood product usage. The Quantra System uses innovative SEER Sonorheometry (Sonic Estimation of Elasticity via Resonance), a proprietary medical-grade ultrasound technology that measures the coagulation properties of a whole blood sample. HemoSonics’ Quantra System is FDA-cleared for cardiovascular surgery, trauma, liver transplantation, and major orthopedic surgery. It requires minimal resources to maintain, is easy to operate and interpret, and enables hospitals to standardize a clinically and operationally efficient viscoelastic testing program.

The company has effectively utilized a variety of communication channels, including targeted marketing campaigns, informative webinars, and engaging social media content, to articulate the benefits of its technology. Detailed case studies showcasing successful implementations of the Quantra system have highlighted improvements in patient outcomes and reductions in unnecessary blood transfusions. Additionally, HemoSonics’ Quantra Hemostasis System technology has received numerous accolades, including the 2024 TIME Best Inventions, 2024 Fast Company Most Innovative Companies (Medtech), 2024 Edison Awards (Point-of-Care and Therapeutic Solutions), and the 2024 Deloitte Fast 500, which recognizes the fastest-growing companies in North America.

HemoSonics has also established itself as a thought leader by addressing critical issues in blood management through various platforms, including earned media coverage, opinion editorial articles, and podcasts. The company’s leadership team regularly publishes insightful content discussing emerging trends in coagulation testing and patient blood management. By engaging with key opinion leaders and participating in relevant conferences, HemoSonics shares its expertise while gathering feedback that informs future product development and marketing strategies.

“We strive to improve patient outcomes and reduce hospital costs each and every day with the Quantra Hemostasis System. The more hospitals and practitioners who know about and adopt Quantra, the greater our ability to help more people becomes,” said Bob Roda, HemoSonics President and CEO. “Marketing, awareness and communications are a key part of our strategy around educating healthcare professionals about how our innovation enables patient-centered decision-making.”

The Medical Device Network Excellence Awards are an independent recognition program, powered by GlobalData. The awards analyze over one billion datasets to recognize top-tier companies and their achievements across more than 200 countries. This award underscores HemoSonics' position as a leader in innovation and marketing within the medical devices sector.

About HemoSonics:

HemoSonics, LLC is a medical device technology company focused on acute bleeding management, resulting in better patient care and lower overall medical costs. The Quantra Hemostasis Analyzer, HemoSonics' flagship product, is designed to improve patient outcomes and reduce healthcare costs by providing optimized coagulation information. The Quantra System's easy and fast interpretation enables simple, more efficient point-of-care and laboratory bleeding management.

Based in Durham, North Carolina, HemoSonics is part of the Stago Group, a leading in vitro diagnostics company dedicated to exploring thrombosis and hemostasis. Visit HemoSonics.com to learn more.